logo

Abeona Therapeutics Inc. (ABEO)



Trade ABEO now with
  Date
  Headline
5/18/2021 7:37:13 AM Abeona Therapeutics Q1 Loss Per Share $0.17 Vs Loss $0.52 Last Year
3/22/2021 7:37:50 AM Abeona Therapeutics Appoints Michael Amoroso As CEO
1/25/2021 7:49:33 AM Abeona Announces Successful Type B Meeting With FDA For Pivotal Phase 3 VIITAL Study Of EB-101
8/17/2020 7:09:55 AM Abeona Therapeutics And Taysha Gene Therapies Enter Licensing And Inventory Purchase Agreements For ABO-202
7/9/2020 7:42:52 AM Abeona Therapeutics Appoints Michael Amoroso As Chief Commercial Officer
7/8/2020 7:34:40 AM Abeona Reinitiates Enrollment In EB-101 Pivotal Phase 3 VIITAL Study In RDEB
6/17/2020 7:36:31 AM Abeona Therapeutics Names George Migausky And Paul Mann Independent Directors
3/17/2020 7:47:24 AM Abeona: First Patient Treated In Pivotal Phase III Clinical Trial On EB-101
1/23/2018 7:29:01 AM RBC Capital Markets Is Lowering ABEONA THERAPEUTICS INC. (ABEO) FY19 Estimate To -0.61 From -0.44